Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis
Authors:
Open Access
- 27 February 2022
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Surgery
- Vol. 14 (2) , 161-173
Abstract
Laparoscopic total gastrectomy (LTG) has drawn increasing attention over the years. Although LTG has shown surgical benefits compared to open TG (OTG) in early stage gastric cancer (GC), little is known about the surgical and oncological outcomes of LTG for advanced GC following neoadjuvant therapy (NAT). To compare the long- and short-term outcomes of advanced GC patients who underwent LTG vs OTG following NAT. Advanced GC patients who underwent TG following NAT between April 2011 and May 2018 at the Cancer Hospital of the Chinese Academy of Medical Sciences were enrolled and stratified into two groups: LTG and OTG. Propensity score matching analysis was performed at a 1:1 ratio to overcome possible bias. In total, 185 patients were enrolled (LTG: 78; OTG: 109). Of these, 138 were paired after propensity score matching. After adjustment for propensity score matching, baseline parameters were similar between the two groups. Compared to OTG, LTG was associated with a significantly shorter length of hospital stay (P = 0.012). The rates of R0 resection, lymph node harvest, and postoperative morbidity did not significantly differ between the two groups. Overall survival (OS) outcomes were comparable between the two groups. Pathological T and N stages were found to be independent risk factors for OS. LTG can be a feasible method for advanced GC patients following NAT, as it appears to be associated with better short- and comparable long-term outcomes compared to OTG.Keywords
This publication has 44 references indexed in Scilit:
- Short-term outcomes of laparoscopic versus open total gastrectomy: a matched-cohort studyThe American Journal of Surgery, 2013
- Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)Journal of Surgical Oncology, 2013
- Comparison of Short-Term Surgical Outcomes Between Laparoscopic and Open Total Gastrectomy for Gastric Carcinoma: Case-Control Study Using Propensity Score Matching MethodJournal of the American College of Surgeons, 2013
- Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysisSurgical Endoscopy, 2012
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III TrialJournal of Clinical Oncology, 2011
- The effects of laparoscopic assisted total gastrectomy on surgical outcomes in the treatment of gastric cancerJournal of the Korean Surgical Society, 2011
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- The Ratio Between Metastatic and Examined Lymph Nodes (N Ratio) Is an Independent Prognostic Factor in Gastric Cancer Regardless of the Type of LymphadenectomyAnnals of Surgery, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004